Alli
Alli (Orlistat) is the only FDA approved weight loss product,that can help losing about 50% more weight than with just dieting alone.
| Product dosage: 60mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.37 | $41.00 (0%) | 🛒 Add to cart |
| 60 | $1.10 | $82.00 $66.00 (20%) | 🛒 Add to cart |
| 90 | $1.01 | $123.00 $91.00 (26%) | 🛒 Add to cart |
| 120 | $0.97 | $164.00 $117.00 (29%) | 🛒 Add to cart |
| 180 | $0.93 | $246.00 $168.00 (32%) | 🛒 Add to cart |
| 270 | $0.90 | $369.00 $243.00 (34%) | 🛒 Add to cart |
| 360 | $0.88
Best per pill | $492.00 $317.00 (36%) | 🛒 Add to cart |
Synonyms | |||
More info:
Glucophage: Advanced Metformin Therapy for Effective Blood Sugar Control
Glucophage, the pioneering brand of metformin hydrochloride, stands as a first-line pharmacological intervention in the management of type 2 diabetes mellitus. This biguanide-class medication operates by addressing core pathophysiological defects: reducing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. Its well-established efficacy, favorable safety profile, and extensive clinical history make it a cornerstone of modern diabetology. Prescribed by healthcare professionals worldwide, Glucophage represents a critical tool in achieving and maintaining glycemic targets, thereby reducing the risk of diabetes-related complications.
Glucovance: Advanced Dual-Action Therapy for Type 2 Diabetes Management
Glucovance represents a significant advancement in the pharmacological management of type 2 diabetes mellitus, combining two well-established antihyperglycemic agents into a single, convenient formulation. This fixed-dose combination therapy synergistically targets multiple pathophysiological defects characteristic of type 2 diabetes, offering clinicians a powerful tool for achieving and maintaining glycemic control. By addressing both insulin resistance and impaired insulin secretion, Glucovance provides a comprehensive approach to diabetes management that can help reduce hemoglobin A1c levels effectively while minimizing polypharmacy.
Glycomet SR: Advanced Sustained-Release Metformin for Type 2 Diabetes Management
Glycomet SR is a pharmaceutical formulation of metformin hydrochloride, designed with a sustained-release mechanism to optimize glycemic control in patients with type 2 diabetes mellitus. As a biguanide-class oral antihyperglycemic agent, it functions primarily by reducing hepatic glucose production and enhancing peripheral insulin sensitivity. This extended-release formulation allows for once-daily dosing, improving patient adherence while minimizing gastrointestinal side effects commonly associated with immediate-release metformin. Clinical evidence supports its efficacy in lowering both fasting and postprandial blood glucose levels, with additional benefits on lipid metabolism and potential cardiovascular risk reduction.
Glycomet: Advanced Glycemic Control for Type 2 Diabetes
Glycomet is a widely prescribed oral antidiabetic medication containing metformin hydrochloride, designed to help manage blood glucose levels in adults with type 2 diabetes. As a first-line therapy, it works by reducing hepatic glucose production and improving insulin sensitivity in peripheral tissues. When combined with diet and exercise, Glycomet supports sustainable metabolic health and reduces the risk of diabetes-related complications. Trusted by healthcare professionals globally, it offers a balance of efficacy and safety for long-term glycemic management.
Metformin: The Cornerstone of Type 2 Diabetes Management
Metformin hydrochloride is a first-line, biguanide-class oral antihyperglycemic agent, widely recognized as the foundational pharmacological therapy for the management of type 2 diabetes mellitus (T2DM). Its primary mechanism of action involves decreasing hepatic glucose production (gluconeogenesis) and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. Unlike many other antidiabetic agents, metformin is not associated with weight gain and carries a low risk of hypoglycemia when used as monotherapy, making it a preferred initial choice for clinicians worldwide.
Actoplus Met: Dual-Action Control for Type 2 Diabetes
Actoplus Met combines two proven antihyperglycemic agents, pioglitazone and metformin, into a single tablet to provide comprehensive glycemic management for adults with type 2 diabetes mellitus. This fixed-dose combination therapy targets two key pathophysiological defects of the disease—insulin resistance and hepatic glucose overproduction—offering a synergistic approach to lower both fasting and postprandial blood glucose levels. By addressing multiple mechanisms simultaneously, it can simplify treatment regimens and improve adherence, which is critical for long-term metabolic control and reducing the risk of diabetes-related complications.
Actos: Advanced Type 2 Diabetes Management with Pioglitazone
Actos (pioglitazone hydrochloride) is a thiazolidinedione-class oral antidiabetic agent indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. By enhancing insulin sensitivity in peripheral tissues, it addresses core pathophysiological defects associated with the disease. This medication is designed for long-term management, helping to stabilize blood glucose levels and potentially reduce the risk of diabetic complications when used as part of a comprehensive treatment plan under medical supervision.
Amaryl: Advanced Glycemic Control for Type 2 Diabetes
Amaryl (glimepiride) is a second-generation sulfonylurea oral antidiabetic agent indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It functions primarily by stimulating insulin secretion from the pancreatic beta cells. This medication is recognized for its once-daily dosing convenience and its role in comprehensive diabetes management strategies, often used both as monotherapy and in combination with other antihyperglycemic agents when needed.
Baclofen: Effective Muscle Spasticity Relief for Enhanced Mobility
Baclofen is a centrally-acting skeletal muscle relaxant primarily indicated for the management of muscle spasticity. It functions as a gamma-aminobutyric acid (GABA) derivative, specifically targeting GABA-B receptors within the spinal cord to inhibit monosynaptic and polysynaptic reflex transmission. This pharmacological action results in reduced muscle tone and frequency of spasms, offering significant symptomatic relief for patients with neurological conditions. Clinicians value baclofen for its targeted mechanism and well-established efficacy profile in both oral and intrathecal formulations.